SULINDAC

Post-LOE

sulindac

Teva

ANDAORALTABLET

Approved

Jun 1993

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

SULINDAC (sulindac) by Teva is cyclooxygenase inhibitors [moa]. Approved for rheumatoid arthritis, rheumatoid arthritis. First approved in 1993.

Drug data last refreshed 19h ago

Mechanism of Action

Cyclooxygenase Inhibitors

Indications (1)

Rheumatoid arthritis

Clinical Trials (2)

NCT04823052Phase 2Withdrawn

Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

Started May 2022

Fragile X Syndrome

NCT00392665Phase 2Terminated

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Started Oct 2006

36 enrolled

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Company

Worked on SULINDAC at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.